title: A Case of Persistent Helicobacter pylori Infection Occurring with Anti-IgE Immunosuppression.
abstract: The increasingly widespread use of novel immunosuppressive drugs may lead to unexpected infectious complications. We report a case of persistent Helicobacter pylori (H. pylori) infection that failed to respond to antimicrobial therapy in a patient receiving omalizumab (Xolair™, Genentech USA Inc., San Francisco, CA and Novartis Pharmaceuticals, Basel, Switzerland), an anti-IgE monoclonal antibody approved by the FDA for treatment of severe persistent asthma. To our knowledge, this is the first case report linking an immunosuppressive regimen containing anti-IgE biologic therapy to persistent H. pylori infection.
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Rhode Island Hospital, The Warren Alpert School of Medicine of Brown University, Providence, RI.
authors.forename: Daniel
authors.initials: D
authors.lastname: Zandman
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Rhode Island Hospital, The Warren Alpert School of Medicine of Brown University, Providence, RI.
authors.forename: William
authors.initials: W
authors.lastname: Hahn
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Rhode Island Hospital, The Warren Alpert School of Medicine of Brown University, Providence, RI.
authors.forename: Steven
authors.initials: S
authors.lastname: Moss